KRAS and non-small cell lung carcinoma: Samples with hotspot mutations in EGFR, KRAS, or BRAF were used as negative controls for fusions and vice versa, to capitalize on known mutual exclusivity of key oncogenic drivers in NSCLC; the specificity of the assay was 100% for both types of alterations.